Company news

Arovella Therapeutics Limited news in 2025

Arovella Therapeutics Limited's news releases, calls and decks from 2025, newest first.

View company

Arovella Therapeutics appoints former CSL CSO Dr Andrew Nash as Non-executive Director

November 11, 2025

Positive FDA Type D Meeting Outcome

October 27, 2025

CLDN18.2 CAR-T cells eliminate pancreatic cancer cells

October 2, 2025

Arovella receives R&D tax rebate of $3.21 million

September 22, 2025

S&P DJI Announces September 2025 Quarterly Rebalance

September 5, 2025

Appendix 4E and Annual Report

August 21, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Research Agreement with University of North Carolina

March 3, 2025

Reinstatement to Official Quotation

February 25, 2025

Prospectus

February 25, 2025

Arovella $15m Placement to fund Phase 1

February 25, 2025

Voluntary Suspension

February 9, 2025

Trading Halt

February 5, 2025

Arovella $20m Placement - fully funded to complete Phase 1

January 9, 2025

Decks in 2025